Global Payer Research
TACS Australia has been working with the FingerPost Consulting team of launch and pricing experts since 2019 to conduct and deliver global level projects, as well as primary and secondary market research in Australia and Japan.
Situation:
Following completion of US and EU pricing research for their first cell therapy, a multi-national company wanted to ensure alignment with other key markets before finalising the global pricing strategy.
Involvement:
Led development of market feasibility and reimbursement strategy reports for Australia, Japan, Korea and Brazil based upon secondary background research and country specific primary research.
Outcome:
The reports provided insights to the emerging regulatory and reimbursement processes for cell and gene therapies, supply and funding arrangements, potential pricing, risk share and pay for performance agreements that are likely to be encountered in each market.
Case Study
Analogue Review
Situation:
A head office team wanted to inform the global reimbursement strategy for a biomarker specific NCE with positive Phase 3 data.
Involvement:
They requested a review of recent decisions by 12 HTA agencies in the therapeutic area, especially for a drug targeting the same biomarker which was performing poorly in terms of global sales.
Outcome:
The drug targeting the same biomarker had received a majority of negative recommendations following evaluation. Comparators, endpoints, modelling approaches and areas of uncertainty were reviewed and insights provided on key reasons behind the rejections.
